Paul Nguyen, Director of Genitourinary Radiation Oncology, Professor, Vice-Chair of Clinical Research at Dana-Farber Cancer Institute, Associate Program Director at Harvard Radiation Oncology Program, and GU Chair at NRG Oncology, shared NRG Oncology’s post on X, adding:
”I’m so grateful to all of the investigators and patients within NRG Oncology and support from National Cancer Institute, Veracyte, Inc., Johnson and Johnson Innovation, and co-leadership from Dr Oliver Sartor and the deeply missed visionary Felix Feng to get this trial accrued two years ahead of schedule!”
Quoting NRG Oncology’s post:
”PRESS RELEASE: NRG Oncology PREDICT-RT Study Completes Patient Accrual, Tests Individualized Concurrent Therapy and Radiation for High-Risk Prostate Cancer.
More posts featuring Paul Nguyen on OncoDaily.